Micofenolato De Mofetilo Aurovitas (Mycophenolate Mofetil)

Mycophenolate mofetil is used in several immunologically mediated conditions, primarily to suppress abnormal lymphocyte activity.

• Prevention of acute organ rejection: lowers the incidence of graft loss in kidney, heart, liver and other solid‑organ transplants.
• Treatment of lupus nephritis: helps control renal inflammation and proteinuria in systemic lupus erythematosus.
• Prevention of graft‑versus‑host disease: reduces the occurrence and severity of GVHD after hematopoietic stem cell transplantation.

• Mycophenolate mofetil is a selective, reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH). By blocking IMPDH, it reduces guanosine nucleotide synthesis, which is essential for DNA replication in activated T and B lymphocytes, thereby inhibiting their proliferation and dampening the immune response.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects

• Nausea: mild to moderate gastrointestinal upset.
• Diarrhea: frequent loose stools, may lead to dehydration.
• Headache: transient cranial discomfort.
• Abdominal pain: cramping or discomfort in the stomach area.
• Infections: increased susceptibility to bacterial, viral or fungal infections.

Serious or Rare Side Effects

• Leukopenia: significant reduction in white blood cell count.
• Severe infections: opportunistic infections such as Pneumocystis jirovecii pneumonia.
• Hepatic toxicity: elevated liver enzymes or hepatitis.
• Malignancy: increased risk of post‑transplant lymphoproliferative disorder.
• Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease of the central nervous system.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor laboratory parameters.

• Pregnancy: Category D – avoid use unless benefits outweigh risks.
• Renal impairment: assess renal function and adjust dose as needed.
• Hepatic impairment: monitor liver enzymes regularly.
• Infection risk: screen for latent infections and vaccinate appropriately before treatment.
• Live vaccines: contraindicated during therapy due to immunosuppression.
• Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture and direct sunlight.

Mycophenolate mofetil may interact with several concomitant medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Live vaccines: may cause severe infection.
• Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole): increase mycophenolate exposure and toxicity.
• Antacids containing magnesium or aluminum: reduce oral absorption of mycophenolate.
• Azathioprine: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely)

• Mycophenolic acid formulations: concurrent use may increase adverse effects.
• High‑dose steroids: may augment immunosuppressive effect.
• Vaccines (inactivated): monitor immune response efficacy.